Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients With EGFRm Advanced NSCLC

被引：3

作者：

Zhou, C. ^{[1
]}

Cheng, Y. ^{[2
]}

He, Y. ^{[3
]}

Li, W. ^{[4
]}

Zhang, H. ^{[5
]}

Zhou, Q. ^{[6
,7
]}

Wang, B. ^{[8
]}

Liu, C. ^{[9
]}

Ramalingam, S. ^{[10
]}

Walding, A. ^{[11
]}

Saggese, M. ^{[11
]}

Wang, J. ^{[12
]}

Fan, M. ^{[12
]}

Wu, Y. ^{[6
,7
]}

机构：

[1] Tongji Univ, Pulm Hosp, Shanghai, Peoples R China

[2] Jilin Prov Canc Hosp, Thorac Oncol, Changchun, Jilin, Peoples R China

[3] Daping Hosp, Resp Dis, Chongqing, Peoples R China

[4] Jinlin Univ, Hosp 1, Changchun, Jilin, Peoples R China

[5] Forth Mil Med Univ, Tangdu Hosp, Oncol, Xian, Shaanxi, Peoples R China

[6] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China

[7] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China

[8] Yangzhou Univ, Subei PeopleS Hosp, Dept Oncol, Yangzhou, Jiangsu, Peoples R China

[9] Xinjiang Med Univ, Tumor Hosp, Urumqi, Peoples R China

[10] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA

[11] Astrazeneca, Global Med Dev, Cambridge, England

[12] Astrazeneca, Global Med Dev, Shanghai, Peoples R China

来源：

JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期

关键词：

osimertinib; China; NSCLC;

D O I：

10.1016/j.jtho.2018.08.669

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.01-112

引用

页码：S507 / S508

页数：2

共 50 条

[41] Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC [J].

Saw, Stephanie P. L. ;

Low, Yi Fen ;

Lai, Gillianne G. Y. ;

Chan, Landon L. ;

Wong, Wesley K. Y. ;

Tsui, Giselle ;

Chen, Olivia H. ;

Seet, Amanda O. L. ;

Tan, Wei Chong ;

Tan, Aaron C. ;

Chan, Johan W. K. ;

Teh, Yi Lin ;

Tan, Wan -Ling ;

Ng, Quan Sing ;

Ang, Mei-Kim ;

Kanesvaran, Ravindran ;

Lim, Darren W. T. ;

Tan, Daniel S. W. ;

Mok, Tony S. K. ;

Li, Molly S. C. .

LUNG CANCER, 2024, 193

[42] First-line osimertinib compared to earlier generation TKIs in advanced EGFR-mutant NSCLC: A real-world survival analysis [J].

Gomez-Randulfe, Igor ;

Scanlon, Lauren A. ;

Carter, Mathew ;

Moliner, Laura ;

Cil, Emine ;

Califano, Raffaele ;

Summers, Yvonne ;

Blackhall, Fiona ;

Lindsay, Colin R. ;

Lewis, Jacob ;

Gomes, Fabio .

LUNG CANCER, 2025, 200

[43] Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell lung cancer with brain metastases: a retrospective cohort study [J].

He, Zhi-Yong ;

Liu, Mei-Fang ;

Lin, Jing-Hui ;

Lin, Dong ;

Lin, Ren-Jang .

CANCER MANAGEMENT AND RESEARCH, 2019, 11 :2129-2138

[44] T790M Detection Rate After First-Line Treatment with Bevacizumab Plus 1st or 2nd Generation EGFR-TKI in Advanced NSCLC [J].

Kuo, C. -H. ;

Su, P. -L. ;

Wei, Y. -F. ;

Ko, J. -C. ;

Tseng, J. -S. ;

Su, J. ;

Chiang, C. -L. ;

Chen, C. -Y. ;

Lin, C. -C. ;

Wang, C. -C. ;

Ho, C. -C. ;

Chang, H. C. ;

Hung, J. -Y. .

JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) :S409-S410

[45] The Feasibility of Osimertinib Treatment on Brain Metastases in NSCLC Patients After 1st Generation EGFR-TKI Resistance: A Preliminary Study [J].

Zhu, L. ;

Zhang, S. ;

Xia, B. ;

Chen, X. ;

Ma, S. .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) :S1738-S1738

[46] EGFR Tyrosine Kinase Inhibitor (TKI) Combined With Concurrent or Sequential Chemotherapy for Patients With Advanced Lung Cancer and Gradual Progression After First-Line EGFR-TKI Therapy: A Randomized Controlled Study [J].

Chang, Qing ;

Xu, Jianlin ;

Qiang, Huiping ;

Teng, Jiajun ;

Qian, Jialin ;

Lv, Minfang ;

Zhang, Yanwei ;

Lou, Yuqing ;

Zhao, Yizhuo ;

Zhong, Runbo ;

Han, Baohui ;

Chu, Tianqing .

CLINICAL LUNG CANCER, 2021, 22 (03) :E395-E404

[47] The Difference in Clinical Outcomes Between Osimertinib and EGFR-TKI plus Anti-angiogenic Agent in EGFR-mutant NSCLC Patients [J].

Huang, Y. H. ;

Hsu, K. -H. ;

Tseng, J. -S. ;

Chen, K. -C. ;

Chang, G. -C. ;

Yang, T. -Y. .

JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) :S477-S478

[48] ORCHARD: A Phase II Platform Study in Patients with Advanced NSCLC Who Have Progressed on First-Line Osimertinib Therapy [J].

Yu, H. ;

Goldberg, S. ;

Le, X. ;

Piotrowska, Z. ;

Smith, P. ;

Mensi, I. ;

Kirova, B. ;

Chmielecki, J. ;

Li-Sucholeicki, X. ;

Szekeres, P. ;

Doughton, G. ;

Patel, G. ;

Jewsbury, P. ;

Riess, J. .

JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) :S647-S647

[49] Efficacy of osimertinib for the treatment of previously EGFR TKI treated NSCLC patients: a meta-analysis [J].

Z.-X. Li ;

W. Zhao ;

Q. Sun ;

M.-S. Tang ;

Q.-J. Xia ;

M.-S. Dong .

Clinical and Translational Oncology, 2020, 22 :892-899

[50] MRI Radiomics Approach to Predict the Intracranial Efficacy of the Third Generation EGFR-TKI Osimertinib in NSCLC Patients with Brain Metastases [J].

Tang, X. ;

Li, Y. ;

Qian, W. -L. ;

Han, P. -L. ;

Yan, W. -F. ;

Yang, Z. -G. .

JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) :S349-S349

← 1 2 3 4 5 →